Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 658K | 0 | 0 | 0 |
| Gross Profit | -3M | -580K | -513K | -560K | -748K |
| Operating Income | -8M | -9M | -10M | -11M | -11M |
| EBITDA | -7M | -7M | -9M | -10M | -10M |
| Net Income | -8M | 5M | -7M | -6M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.322
-4.45% today
1Y Change
-81.55%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scinai Immunotherapeutics Ltd. (SCNI) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.32 and down 81.6% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of +99.2%, EPS growth of -160.0%, a dividend yield of 0.0%. What stands out right now is revenue +99.2%, EPS -160.0%, free cash flow +4.6% with operating margin -574.0% and ROIC -72.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SCNI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCNI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCNI Max Drawdown
-83.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCNI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$8.2M
-41.6% YoY
Free Cash Flow
-$7.6M
+6.6% YoY
Revenue Growth
+99.2%
EPS Growth
-160.0%
Gross Margin
-201.8%
Net Margin
-632.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 658K | 0 | 0 | 0 |
| Gross Profit | -3M | -580K | -513K | -560K | -748K |
| Operating Income | -8M | -9M | -10M | -11M | -11M |
| EBITDA | -7M | -7M | -9M | -10M | -10M |
| Net Income | -8M | 5M | -7M | -6M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 5M | 14M | 17M |
| Total Assets | 12M | 13M | 17M | 27M | 32M |
| Total Liabilities | 4M | 3M | 22M | 29M | 31M |
| Shareholder Equity | 8M | 10M | -5M | -2M | 982K |
| Total Debt | 2M | 2M | 21M | 22M | 29M |
| Net Debt | 606K | 122K | 16M | 7M | 12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
-2.2% YoY
Capital Expenditures
133K
+84.1% YoY
Free Cash Flow
8M
+6.6% YoY
Key ratios
Gross Margin
-201.8%
Operating Margin
-574.0%
Net Margin
-632.2%
ROE
-98.3%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.